NTLA

Conviction 38HealthcareScan · Thu, Sep 24, 2026

Intellia Therapeutics, Inc. (NTLA) closed at $12.17 (-1.30%) on Sep 24, 2026. Price is above its 50-day and below its 200-day moving average. RSI(14) 49, RS Rating 18, -56.5% from its 52-week high, +32.1% year to date. Sector: Healthcare · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.

NTLA$12.17-1.30%

ResistanceSupportVol 14Insider sell

Vol MA14 4.48M

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

Intellia Therapeutics, Inc.IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCESwww.intelliatx.com ↗

Price12.17

Change-1.30%

Gap-2.19%

Rel volume1.57×

Avg volume4M

Avg $ vol49.16M

SMA 2012.34

SMA 5011.94

SMA 20012.77

Price vs 50+1.92%

Price vs 200-4.73%

MA stackmixed

50/200 crossdeath · 9d

Supertrendup · 11.07

RSI (14)49

MACD hist0.02

MACD crossbull · 2d

Stoch %K / %D54 / 64

ADX (14)14

+DI / −DI22 / 19

RSI divergence—

MACD divergence—

ATR %5.62%

ADR %4.70%

52w high27.98

52w low8.04

From 52w high-56.50%

Above 52w low+51.37%

New 52w highNo

SqueezeOn · 1d

Bollinger width15.24%

%B0.41

Donchian pos41.26%

Donchian high13.49

Donchian low11.24

AVWAP (52w high)12.96

vs AVWAP high-6.12%

AVWAP (52w low)12.84

vs AVWAP low-5.20%

OBV trendDown

Chaikin MF (20)-0.08

Today vs 20d1.57×

Avg vol (14d)4.48M

Avg vol (20d)4M

Avg $ vol (20d)49.16M

Market cap1.71B

RS Rating18 / 99

RS 3m (vs SPY)-28.57%

RS 6m (vs SPY)-25.04%

RS line new highNo

Trend template4/8

Technical rank40.3

1 week-0.73%

1 month-9.92%

3 months-24.08%

6 months-8.22%

1 year-28.75%

YTD+32.14%

P/E-4.13

P/B2.34

P/S25.20

P/FCF-4.31

EPS-3.81

Div yield—

ROE-56.71%

ROA-48.15%

Debt/Eq—

Current6.65

EV/EBITDA-3.71

Gross margin—

Net margin-609.85%

Rev growth16.92%

EPS growth20.49%

Price target20.50

Target upside68.45%

Analyst ratingBuy

Institutional113.73%

Ent. value1.6B

Revenue7.66M

Net income-106.63M

Gross profit—

Free cash flow-395.87M

IndustryIN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

ExchangeNasdaq

Shares out139.72M

Employees377

ListedFri, May 6, 2016

Free float96.07M

Float %82.9%

Short interest43.93M

Days to cover12.9d

Short volume65.2%

Squeeze score90 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.80 vs −$0.80

Last surprise0.0% beat

Setup gradeD

Conviction38 / 100

Pattern quality—

Tech rank40.3 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance13.54

Support10.52

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in NTLA

All disclosures →

No recent disclosed trades by Congress in NTLA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in NTLA · open-market 2 sells

Insider	Side	Shares	Value	Traded	Filed
LEONARD JOHN M President and CEO · Common Stock · 2026-08-21	Sell	2.79K	$36K	2026-08-21	2026-08-24
LEONARD JOHN M President and CEO · Common Stock · 2026-08-20	Sell	19.89K	$251K	2026-08-20	2026-08-24
Verwiel Frank Director · Common Stock · 2026-06-09	Grant	9.2K	$0	2026-06-09	2026-06-10
Bhanji Muna Director · Stock Option (right to buy) · 2026-06-09	Grant	13.3K	$0	2026-06-09	2026-06-10
Keresty Georgia Director · Common Stock · 2026-06-09	Grant	9.2K	$0	2026-06-09	2026-06-10
Keresty Georgia Director · Stock Option (right to buy) · 2026-06-09	Grant	13.3K	$0	2026-06-09	2026-06-10
GOODMAN JESSE Director · Common Stock · 2026-06-09	Grant	9.2K	$0	2026-06-09	2026-06-10
GOODMAN JESSE Director · Stock Option (right to buy) · 2026-06-09	Grant	13.3K	$0	2026-06-09	2026-06-10
CHASE WILLIAM J Director · Common Stock · 2026-06-09	Grant	9.2K	$0	2026-06-09	2026-06-10
Verwiel Frank Director · Stock Option (right to buy) · 2026-06-09	Grant	13.3K	$0	2026-06-09	2026-06-10

SEC filings

EDGAR filings in NTLA · 9 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.